We are pleased to announce that on 18 May 2022, China Merchants Securities (HK) Co., Limited (“CMS (HK)”, a subsidiary of China Merchants Securities International Company Limited), acting as one of the Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers of Yunkang Group Limited (“Yunkang” or “the Company”, stock code: 2325.HK), successfully assisted the Company to commence trading of its shares on the Main Board of The Stock Exchange of Hong Kong Limited (“HKEx”). A total of approximately 138 million shares are offered (which comprises of approximately 113 million new shares and 25 million old shares) under the Global Offering, at an offer price of HK$7.89 per share, raising a total of approximately HK$1.09 billion (before the exercise of the over-allotment option) or HK$1.25 billion (assuming the over-allotment option is fully exercised).
Despite the current volatile market conditions and various macroeconomic uncertainties, CMS (HK) rose to the challenge, unswervingly marched forward with the marketing efforts and successfully assisted the Company to complete its public listing in Hong Kong, setting a milestone for the China medical operation services industry. As one of the Joint Global Coordinators, CMS (HK) accompanied Yunkang to overcome difficulties along the way, catered to the needs of the Company and investors building upon our extensive project experience, contributing to the successful listing with the trust and support from the Company.
Leveraging our strong sales force and valuable client resources both locally and abroad, CMS (HK) selectively arranged top international and Chinese investors including long-only funds, private equity funds, multi-strategy funds, corporate investors and family offices to participate in investor meetings, investor education events and management roadshow meetings, maximizing the publicity of the Company in the capital markets. Through continuous and timely communication with investors and our in-depth understanding of the healthcare sector, CMS (HK) fully showcased to investors Yunkang’s unique strengths and investment highlights. Furthermore, in order to expedite the smooth preparation process, CMS (HK) coordinated expertise from onshore and offshore teams as an integrated platform, provided value-added services, including account opening and margin financing services, and remained highly engaged throughout the process.
CMS (HK) thrived on the fluctuating market conditions, persisted in the critical bookbuilding process and continued to further our investor outreach, and eventually secured multiple renowned institutional investors as sole or anchor orders, laying a solid foundation for the successful public offering of the Company.
About Yunkang Group Limited
Yunkang is a medical operation service provider in China offering a full suite of diagnostic testing services for medical institutions with a market share of 3.7% in China’s medical operation service market in terms of revenue in 2020. Medical operation services provided by the Company include diagnostic outsourcing services and diagnostic testing services for medical institution alliances. The Company is a major market player in China’s diagnostic testing services for medical institution alliances market, with a market share of 12.5% in terms of revenue in 2020.